Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CLINICAL MEASUREMENT - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).
Term:tumor incidence/prevalence measurement
go back to main search page
Accession:CMO:0000927 term browser browse the term
Definition:A measurement in which the number of individuals in a study population displaying at a point in time one or more tumors--that is, abnormal growth(s) of tissue resulting from uncontrolled, progressive multiplication of cells which serve no physiological function-- of a particular organ or developing such growths within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.


show annotations for term's descendants           Sort by:
mammary tumor incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Mcs31 Mammary carcinoma susceptibility QTL 31 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 9:77,813,894...111,552,878 JBrowse link
Q Mcs32 Mammary carcinoma susceptibility QTL 32 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 1:115,540,693...238,914,717 JBrowse link
Q Mcs33 Mammary carcinoma susceptibility QTL 33 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 5:131,345,754...166,875,058 JBrowse link
Q Mcs34 Mammary carcinoma susceptibility QTL 34 IDA RGD PMID:23967281 RGD:7794780
percentage of study population developing mammary tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Emca4 Estrogen-induced mammary cancer QTL 4 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 7:62,004,452...101,773,158 JBrowse link
Q Emca5 Estrogen-induced mammary cancer QTL 5 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 3:43,827,364...169,034,231 JBrowse link
percentage of study population developing T-cell lymphomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tls2 T-lymphoma susceptibility QTL 2 IDA RGD PMID:10360666 RGD:619600 NCBI chr 7:80,221,299...109,401,111 JBrowse link
Q Tls3 T-lymphoma susceptibility QTL 3 IDA RGD PMID:10360666 RGD:619600 NCBI chr10:51,774,612...95,600,334 JBrowse link
percentage of study population developing testis tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tescar1 Testicular tumor resistance QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr11:1,041,931...66,113,562 JBrowse link
percentage of study population developing trigeminal nerve neurilemmomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Schws1 Schwannoma susceptibility QTL 1 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:40,035,094...102,359,817 JBrowse link
Q Schws2 Schwannoma susceptibility QTL 2 IDA RGD PMID:16003739 RGD:1559300
Q Schws3 Schwannoma susceptibility QTL 3 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 3:118,839,124...163,839,124 JBrowse link
Q Schws4 Schwannoma susceptibility QTL 4 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 6:83,190,345...106,747,639 JBrowse link
Q Schws7 Schwannoma susceptibility QTL 7 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:4,765,527...19,816,042 JBrowse link
Q Schws8 Schwannoma susceptibility QTL 8 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:94,968,928...139,968,928 JBrowse link
Q Schws9 Schwannoma susceptibility QTL 9 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:61,747,639...106,747,639 JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  clinical measurement 2369
    tumor measurement 88
      tumor incidence/prevalence measurement 16
        colorectal tumor incidence/prevalence measurement + 0
        endometrial adenocarcinoma incidence/prevalence measurement + 0
        intestine tumor incidence/prevalence measurement + 0
        liver tumor incidence/prevalence measurement + 0
        lung tumor incidence/prevalence measurement + 0
        lymphoma incidence/prevalence measurement + 2
        mammary tumor incidence/prevalence measurement + 6
        neurilemmoma incidence/prevalence measurement + 7
        pituitary tumor incidence/prevalence measurement + 0
        prostate tumor incidence/prevalence measurement + 0
        stomach tumor incidence/prevalence measurement + 0
        subcutaneous tumor incidence/prevalence measurement + 0
        testis tumor incidence/prevalence measurement + 1
Path 2
Term Annotations click to browse term
  clinical measurement 2369
    organ measurement 485
      organ lesion measurement 140
        organ tumorous lesion measurement 108
          organ tumorous lesion incidence/prevalence measurement 18
            tumor incidence/prevalence measurement 16
              colorectal tumor incidence/prevalence measurement + 0
              endometrial adenocarcinoma incidence/prevalence measurement + 0
              intestine tumor incidence/prevalence measurement + 0
              liver tumor incidence/prevalence measurement + 0
              lung tumor incidence/prevalence measurement + 0
              lymphoma incidence/prevalence measurement + 2
              mammary tumor incidence/prevalence measurement + 6
              neurilemmoma incidence/prevalence measurement + 7
              pituitary tumor incidence/prevalence measurement + 0
              prostate tumor incidence/prevalence measurement + 0
              stomach tumor incidence/prevalence measurement + 0
              subcutaneous tumor incidence/prevalence measurement + 0
              testis tumor incidence/prevalence measurement + 1
paths to the root